Literature DB >> 21047515

Functional effects of a tropomyosin mutation linked to FHC contribute to maladaptation during acidosis.

Katherine A Sheehan1, Grace M Arteaga, Aaron C Hinken, Fernando A Dias, Cibele Ribeiro, David F Wieczorek, R John Solaro, Beata M Wolska.   

Abstract

Familial hypertrophic cardiomyopathy (FHC) is a leading cause of sudden cardiac death among young athletes but the functional effects of the myofilament mutations during FHC-associated ischemia and acidosis, due in part to increased extravascular compressive forces and microvascular dysfunction, are not well characterized. We tested the hypothesis that the FHC-linked tropomyosin (Tm) mutation Tm-E180G alters the contractile response to acidosis via increased myofilament Ca(2+) sensitivity. Intact papillary muscles from transgenic (TG) mice expressing Tm-E180G and exposed to acidic conditions (pH 6.9) exhibited a significantly smaller decrease in normalized isometric tension compared to non-transgenic (NTG) preparations. Times to peak tension and to 90% of twitch force relaxation in TG papillary muscles were significantly prolonged. Intact single ventricular TG myocytes demonstrated significantly less inhibition of unloaded shortening during moderate acidosis (pH 7.1) than NTG myocytes. The peak Ca(2+) transients were not different for TG or NTG at any pH tested. The time constant of re-lengthening was slower in TG myocytes, but not the rate of Ca(2+) decline. TG detergent-extracted fibers demonstrated increased Ca(2+) sensitivity of force and maximal tension compared to NTG at both normal and acidic pH (pH 6.5). Tm phosphorylation was not different between TG and NTG muscles at either pH. Our data indicate that acidic pH diminished developed force in hearts of TG mice less than in NTG due to their inherently increased myofilament Ca(2+) sensitivity, thus potentially contributing to altered energy demands and increased propensity for contractile dysfunction.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21047515      PMCID: PMC3035739          DOI: 10.1016/j.yjmcc.2010.10.032

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  43 in total

1.  Effects of two familial hypertrophic cardiomyopathy-causing mutations on alpha-tropomyosin structure and function

Authors: 
Journal:  Biochemistry       Date:  1999-03-23       Impact factor: 3.162

2.  Identification of a region of troponin I important in signaling cross-bridge-dependent activation of cardiac myofilaments.

Authors:  Patti L Engel; Tomoyoshi Kobayashi; Brandon Biesiadecki; Jonathan Davis; Svetlana Tikunova; Steven Wu; R John Solaro
Journal:  J Biol Chem       Date:  2006-11-12       Impact factor: 5.157

3.  Alterations of the architecture of subendocardial arterioles in patients with hypertrophic cardiomyopathy and impaired coronary vasodilator reserve: a possible cause for myocardial ischemia.

Authors:  B Schwartzkopff; M Mundhenke; B E Strauer
Journal:  J Am Coll Cardiol       Date:  1998-04       Impact factor: 24.094

4.  Effects of two familial hypertrophic cardiomyopathy-causing mutations on alpha-tropomyosin structure and function.

Authors:  N Golitsina; Y An; N J Greenfield; L Thierfelder; K Iizuka; J G Seidman; C E Seidman; S S Lehrer; S E Hitchcock-DeGregori
Journal:  Biochemistry       Date:  1997-04-15       Impact factor: 3.162

5.  Correlation between myofilament response to Ca2+ and altered dynamics of contraction and relaxation in transgenic cardiac cells that express beta-tropomyosin.

Authors:  B M Wolska; R S Keller; C C Evans; K A Palmiter; R M Phillips; M Muthuchamy; J Oehlenschlager; D F Wieczorek; P P de Tombe; R J Solaro
Journal:  Circ Res       Date:  1999-04-16       Impact factor: 17.367

6.  Altered hemodynamics in transgenic mice harboring mutant tropomyosin linked to hypertrophic cardiomyopathy.

Authors:  C C Evans; J R Pena; R M Phillips; M Muthuchamy; D F Wieczorek; R J Solaro; B M Wolska
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-11       Impact factor: 4.733

7.  A familial hypertrophic cardiomyopathy alpha-tropomyosin mutation causes severe cardiac hypertrophy and death in mice.

Authors:  R Prabhakar; G P Boivin; I L Grupp; B Hoit; G Arteaga; R J Solaro; D F Wieczorek
Journal:  J Mol Cell Cardiol       Date:  2001-10       Impact factor: 5.000

8.  Dual loading of the fluorescent indicator fura-2 and 2,7-biscarboxyethyl-5(6)-carboxyfluorescein (BCECF) in isolated myocytes.

Authors:  H Miyata; H Hayashi; S Suzuki; N Noda; A Kobayashi; H Fujiwake; M Hirano; N Yamazaki
Journal:  Biochem Biophys Res Commun       Date:  1989-08-30       Impact factor: 3.575

9.  Mechanisms of enhanced arrhythmogenicity of regional ischemia in the hypertrophied heart.

Authors:  D Kozhevnikov; Edward B Caref; Nabil El-Sherif
Journal:  Heart Rhythm       Date:  2008-12-24       Impact factor: 6.343

Review 10.  Sarcomeric proteins and inherited cardiomyopathies.

Authors:  Sachio Morimoto
Journal:  Cardiovasc Res       Date:  2007-12-04       Impact factor: 10.787

View more
  9 in total

1.  N-acetylcysteine reverses diastolic dysfunction and hypertrophy in familial hypertrophic cardiomyopathy.

Authors:  Tanganyika Wilder; David M Ryba; David F Wieczorek; Beata M Wolska; R John Solaro
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-10-02       Impact factor: 4.733

Review 2.  Structural determinants of muscle thin filament cooperativity.

Authors:  Jeffrey R Moore; Stuart G Campbell; William Lehman
Journal:  Arch Biochem Biophys       Date:  2016-02-15       Impact factor: 4.013

3.  Mechanistic heterogeneity in contractile properties of α-tropomyosin (TPM1) mutants associated with inherited cardiomyopathies.

Authors:  Tejas M Gupte; Farah Haque; Binnu Gangadharan; Margaret S Sunitha; Souhrid Mukherjee; Swetha Anandhan; Deepa Selvi Rani; Namita Mukundan; Amruta Jambekar; Kumarasamy Thangaraj; Ramanathan Sowdhamini; Ruth F Sommese; Suman Nag; James A Spudich; John A Mercer
Journal:  J Biol Chem       Date:  2014-12-29       Impact factor: 5.157

4.  Elucidation of isoform-dependent pH sensitivity of troponin i by NMR spectroscopy.

Authors:  Ian M Robertson; Peter C Holmes; Monica X Li; Sandra E Pineda-Sanabria; Olga K Baryshnikova; Brian D Sykes
Journal:  J Biol Chem       Date:  2011-12-17       Impact factor: 5.157

5.  Ceramide-mediated depression in cardiomyocyte contractility through PKC activation and modulation of myofilament protein phosphorylation.

Authors:  Jillian N Simon; Shamim A K Chowdhury; Chad M Warren; Sakthivel Sadayappan; David F Wieczorek; R John Solaro; Beata M Wolska
Journal:  Basic Res Cardiol       Date:  2014-10-04       Impact factor: 17.165

6.  Upregulation of cardiomyocyte ribonucleotide reductase increases intracellular 2 deoxy-ATP, contractility, and relaxation.

Authors:  F S Korte; Jin Dai; Kate Buckley; Erik R Feest; Nancy Adamek; Michael A Geeves; Charles E Murry; Michael Regnier
Journal:  J Mol Cell Cardiol       Date:  2011-09-03       Impact factor: 5.000

Review 7.  A Perspective on Personalized Therapies in Hypertrophic Cardiomyopathy.

Authors:  Paul H Goldspink; Chad M Warren; Jan Kitajewski; Beata M Wolska; R John Solaro
Journal:  J Cardiovasc Pharmacol       Date:  2021-03-01       Impact factor: 3.271

8.  Predicting Effects of Tropomyosin Mutations on Cardiac Muscle Contraction through Myofilament Modeling.

Authors:  Lorenzo R Sewanan; Jeffrey R Moore; William Lehman; Stuart G Campbell
Journal:  Front Physiol       Date:  2016-10-26       Impact factor: 4.566

9.  Thin filament incorporation of an engineered cardiac troponin C variant (L48Q) enhances contractility in intact cardiomyocytes from healthy and infarcted hearts.

Authors:  Erik R Feest; F Steven Korte; An-Yue Tu; Jin Dai; Maria V Razumova; Charles E Murry; Michael Regnier
Journal:  J Mol Cell Cardiol       Date:  2014-03-29       Impact factor: 5.000

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.